Integra Lifesciences Holdings Corp represents a set of values and a corporate philosophy that focuses on making a positive impact in the field of healthcare. The company is committed to delivering innovative solutions and technologies, aiming to improve patient outcomes and quality of life. Integra Lifesciences Holdings Corp is guided by principles of integrity, transparency, and collaboration, fostering strong partnerships with healthcare professionals and stakeholders. With a dedication to continuous improvement, the company strives to provide advanced medical devices, regenerative technologies, and specialty products that enhance the lives of patients worldwide. Integra Lifesciences Holdings Corp prioritizes patient-centricity and is dedicated to making a difference in the global healthcare community.

Integra Lifesciences Holdings Corp is primarily present in various countries and regions worldwide. These include the United States, Europe, Asia-Pacific, and Latin America.

Integra Lifesciences Holdings Corp has attained several significant milestones. The company achieved FDA clearance for its DermaTran wound dressing, providing advanced wound care solutions. Additionally, Integra Lifesciences received CE Mark approval for its CUSA Clarity Ultrasonic Surgical Aspirator, enhancing surgical precision and patient outcomes. The company also introduced Codman Enterprise 2 Coil System, an advancement in endovascular treatment for brain aneurysms. Furthermore, Integra Lifesciences acquired Medtronic's MicroFrance and Xomed Surgical Products business units, broadening its product portfolio and market presence. These achievements reflect Integra Lifesciences' commitment to innovation, improving patient care, and expanding its global reach.

Integra Lifesciences Holdings Corp is a renowned global medical device company specializing in advanced surgical instruments and regenerative technologies. Established in 1989, the company has steadily evolved to become a leader in providing innovative solutions for neurosurgery, orthopedics, reconstructive surgery, and wound and tissue management. With a focus on improving patient outcomes, Integra Lifesciences develops and markets a diverse portfolio of products, ranging from implants and implants systems to surgical instruments and medical devices. Throughout its history, Integra Lifesciences has demonstrated a commitment to research, development, and collaboration, continuously enhancing its offerings to meet the evolving needs of healthcare professionals worldwide.

The main competitors of Integra Lifesciences Holdings Corp in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Baxter International Inc.

Integra Lifesciences Holdings Corp is primarily active in the healthcare and medical device industries.

The business model of Integra Lifesciences Holdings Corp is focused on providing innovative medical technologies and solutions that address various healthcare needs. The company operates in three primary segments: Codman Specialty Surgical, Orthopedics and Tissue Technologies, and Neurosurgery. Integra Lifesciences aims to enhance patient outcomes by developing and manufacturing medical devices, implants, instruments, and regenerative products. The company's comprehensive portfolio encompasses products for various medical specialties, including neurosurgery, plastic and reconstructive surgery, orthopedics, and wound care. Integra Lifesciences collaborates with healthcare professionals to offer cutting-edge solutions that improve the quality and efficiency of patient care.

Коефициентът на цена спрямо печалбата (КЦП) на Integra Lifesciences Holdings е 10,35.

Коефициентът на цена към оборот (KUV) на Integra Lifesciences Holdings е 1,48.

AlleAktien качественият резултат за Integra Lifesciences Holdings е 5/10.

очаквана Integra Lifesciences Holdings оборотът е 1,71 млрд. USD.

очаквана Integra Lifesciences Holdings печалба е 243,96 млн. USD.

Integra Lifesciences Holdings Corp is a leading company in the field of medical devices and instruments. It offers a wide range of products and services tailored to the needs of the healthcare industry. The company operates in three main divisions: neurosurgery, plastic & reconstructive surgery, and orthopedics & cell therapy. The neurosurgery division offers a variety of products and services tailored to the needs of neurosurgeons and patients. Integra Lifesciences Holdings Corp develops and produces innovative solutions for the treatment of neurological disorders such as Parkinson's disease. The products include the neuromodulatory system, brain stimulation device, and other technologies that help treat neurological disorders. The plastic & reconstructive surgery division offers solutions for reconstructive and aesthetic surgery. The product range includes a variety of implants, tissue grafts, bone substitutes, and other products tailored to the needs of surgeons. The company works closely with doctors to provide innovative solutions that improve patients' lives. The orthopedics & cell therapy division offers products and services tailored to the needs of orthopedic surgeons and patients. The range includes a wide range of products, such as artificial joints and bone grafts. Integra Lifesciences Holdings Corp also offers innovative cell therapy solutions. In addition to the mentioned divisions, other products are available, such as maggot cultures for wound therapy. The company places great emphasis on quality and research. It continuously invests in research and development and works closely with doctors and researchers to provide innovative solutions. Integra Lifesciences Holdings Corp has a broad customer base throughout Europe and North America and works closely with doctors, clinics, and hospitals to ensure the best possible patient care. Overall, Integra Lifesciences Holdings Corp offers innovative and individual solutions in the specialized field of healthcare through its wide range of products and research.

Integra Lifesciences Holdings разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Integra Lifesciences Holdings в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Integra Lifesciences Holdings е US4579852082.

WKN на Integra Lifesciences Holdings е 897013.

Тикерът на Integra Lifesciences Holdings е IART.

През последните 12 месеца Integra Lifesciences Holdings изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Integra Lifesciences Holdings да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Integra Lifesciences Holdings в момента е .

Integra Lifesciences Holdings изплаща дивидент на тримесечие. Той се разпределя в месеците .

Integra Lifesciences Holdings платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Integra Lifesciences Holdings се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Integra Lifesciences Holdings на 27.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 27.07.2024 г..

Последното дивидентно плащане беше извършено на 27.07.2024 г..

През година 2023 Integra Lifesciences Holdings изплати 0 USD под формата на дивиденти.

Дивидентите от Integra Lifesciences Holdings се изплащат в USD.